

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中生北控生物科技股份有限公司**  
**BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION**  
*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*  
(Stock Code: 8247)

**INSIDE INFORMATION**  
**IN RELATION TO THE PROPOSED TRANSFER OF H SHARES**  
**BY A SUBSTANTIAL SHAREHOLDER**

This announcement is made by Biosino Bio-Technology and Science Incorporation (the “**Company**”) pursuant to Rule 17.10 of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 14 March 2023, the Company received a notice from Beijing Enterprises Holdings Limited (“**Beijing Enterprises**”), a substantial shareholder of the Company, that Beijing Enterprises intends to dispose of all of 27,256,143 H shares of the Company held by it (representing approximately 42.4% of the number of issued H shares and 18.84% of the total number of issued shares of the Company) by way of solicitation of transferees through a public bidding process (the “**Proposed Transfer**”). As at the date of this announcement, Beijing Enterprises holds a total of 27,256,143 H shares of the Company (representing approximately 42.4% of the number of issued H shares and 18.84% of the total number of issued shares of the Company).

The Proposed Transfer is subject to approval by Beijing Enterprises Group Company Limited (the parent company of Beijing Enterprises) as well as other preconditions. As there is uncertainty on whether such approval(s) can be obtained and the timing for obtaining such approval(s), the Proposed Transfer may or may not proceed.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Biosino Bio-Technology and Science Incorporation**  
**Wu Lebin**  
*Chairman and Executive Director*

Beijing, the People's Republic of China, 14 March 2023

As at the date of this announcement, the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company comprises:

*Chairman and executive Director*

Mr. Wu Lebin (吳樂斌先生)

*Vice chairman and non-executive Director*

Dr. Sun Zhe (孫哲博士)

*Vice chairman and executive Director*

Mr. Lin Yanglin (林楊林先生)

*Non-executive Director*

Ms. Cheng Yali (程亞利女士)

*Independent non-executive Directors*

Dr. Zheng Yongtang (鄭永唐博士), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangan (沈劍剛教授)

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at <http://www.hkexnews.hk> for a minimum of seven days from the date of its publication and on the website of the Company at [www.zhongsheng.com.cn](http://www.zhongsheng.com.cn).*